WASHINGTON--(BUSINESS WIRE)--Joyce A. Cramer, President of the Epilepsy Therapy Project (ETP), will be presenting today, Thursday, July 10, 2008, before the US Food and Drug Administration’s (FDA) Joint Meeting of the Peripheral and Central Nervous Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee on the incidence of suicidality and correlation to pre-existing psychiatric disorders among patients being treated with anti-epilepsy therapeutics. In her comments, Ms. Cramer will both discuss the unintended consequences of proposed FDA actions and also new insights into pre-existing psychiatric disorders and the recognition of co-morbidities that predate the prescribing of seizure disorder medications.
